Persistent Asset Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Persistent Asset Partners’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$517K	Buy	47,663 +20,897	+78%	+$238K	0.15%	109
2026 Q1	$297K	Buy	26,766 +13,850	+107%	+$175K	0.11%	156
2025 Q4	$214K	Buy	+12,916	New	+$184K	0.1%	208
2025 Q3	–	Sell	-9,421	Closed	-$90.3K	–	285
2025 Q2	$90.3K	Buy	+9,421	New	+$52.1K	0.07%	128

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Persistent Asset Partners's PHAT Position: Q2 2026 in Review

Persistent Asset Partners increased its Phathom Pharmaceuticals (PHAT) stake by 78% in Q2 2026, buying an estimated $238K and bringing the position to 47,663 shares worth $517K. The position accounts for 0.15% of the portfolio, ranked #109.

Persistent Asset Partners first reported a position in PHAT in Q2 2025 and has held it in 4 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Persistent Asset Partners held 47,663 shares of Phathom Pharmaceuticals worth $517K as of Q2 2026.
Persistent Asset Partners bought 20,897 Phathom Pharmaceuticals shares in Q2 2026, an estimated $238K.
Phathom Pharmaceuticals made up 0.15% of Persistent Asset Partners's portfolio in Q2 2026, its #109 holding.
Persistent Asset Partners first reported a position in Phathom Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.